Year None20222021202020192018201720162015201420132012 12.02.2022 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.30.2022 Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock 11.30.2022 Iveric Bio Announces Proposed Offering of Common Stock 11.17.2022 Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy 11.04.2022 Iveric Bio to Present at Upcoming Investor Conferences 11.03.2022 Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy 11.03.2022 Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results 11.02.2022 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10.27.2022 Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022 10.04.2022 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
